Klatskin Tumor Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 26, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Klatskin Tumor. It connects disease background, epidemiology, target mechanism, competition, transactions, unmet need and market attractiveness.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Executive assessment

Klatskin Tumor receives a directional score of 63/100, combining unmet need (79/100), competitive intensity (85/100) and market attractiveness (80/100). It is a prioritization framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

Cholangiocarcinoma arising near or at the confluence of the right and left hepatic ducts (COMMON HEPATIC DUCT). These tumors are generally small, sharply localized, and seldom metastasizing.

The reproducible record is Patsnap disease ID e9f251a624f84d63983a2f757bd85782 and MeSH identifier D018285. Stable identifiers prevent historical names, gene-defined subtypes and overlapping syndromic labels from producing inconsistent landscapes.

A target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, setting, safety and endpoint. An overly broad population can inflate market size while weakening biological signal and recruitment. The first population should be biologically coherent and operationally feasible.

Map the pathway from symptom recognition through specialist referral, testing, treatment and monitoring. Diagnostic delay, center concentration and testing access can constrain trials and commercialization as much as drug performance.

Epidemiology and disease burden

Epidemiology evidence 1: 浙江省肿瘤登记地区2008—2019年胃癌5年生存率分析 Five-year survival analysis of gastric cancer from population-based cancer registration data in Zhejiang province, China

[1] 郑荣寿, 张思维, 孙可欣, 等. 2016 年中国恶性肿瘤流行情 况分析[J]. 中华肿瘤杂志, 2023, 45(3): 212-220. DOI: 10.3760/cma.j.cn112152-20220922-00647. [2] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. DOI:10.3322/caac.21660. [3] Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7):783-791. DOI:10.1097/CM9.0000000000001474. [4] 曹毛毛, 李贺, 孙殿钦, 等. 2000—2019 年中国胃癌流行病

Review source

Epidemiology evidence 2: 2022年全球恶性肿瘤统计报告解读 Interpretation on the report of global cancer statistics 2022

近几十年来，许多地区甲状腺癌发病率快速增 长，主要归因于影像学、超声检查以及活检的广泛 应用 ［38-39］。据估计，2003—2007 年，过度诊断病例 占韩国新发甲状腺癌的90%，占美国、意大利、法国 和澳大利亚的70%～80% ［38］。因此，国际上已不再 推荐开展甲状腺癌筛查，建议对微小癌进行积极 监测 ［40-43］。 10. 膀胱癌：膀胱癌是全球发病第9 位的恶性 肿瘤。2022 年全球膀胱癌新发病例61.4 万，死亡 病例22.0万 ［1］，占全部恶性肿瘤发病和死亡的3.1% 和2.3% ［1］（表1）。男性膀胱癌标化发病率（9.3/10万） 和死亡率（3.1/10万）约为女性标化发病率（2.4/10万） 和死亡率（0.8/10万）的3～4倍 ［1］。 11. 非霍奇金淋巴瘤：非霍奇金淋巴瘤位居全 球恶性肿瘤发病第10位，死亡第11位，是最常见的 血液系统恶性肿瘤。2022 年全球非霍奇金淋巴瘤 新发病例55.3 万，死亡病例25.0 万 ［1］，占全部恶性 肿瘤发病和死亡的2.8% 和2.6% ［1］（表1）。男性非 霍奇金淋巴瘤标化发病率（6.6/10 万）和死亡率 （2.9/10 万）约为女性（4.6/10 万和1.9/10 万 ［1］）的 1.5倍（表2）。 12. 白血病：2022 年全球白血病新发病例 48.7 万 ［1］，死亡病例30.5 万，占全部恶性肿瘤发病 和死亡的2.4% ［1］和3.1%（表1），位居全球恶性肿瘤 发病第13位和死亡第10位。

Review source

Epidemiology evidence 3: Brain and Other Central Nervous System Tumor Statistics, 2021

### Chart Data Transcription Report 1. Basic Chart Information * Chart Title: Malignant Brain and Other Central Nervous System Tumor Age-Adjusted Incidence Rates in Adults Aged ≥20 Years by Sex and Race/Ethnicity (CBTRUS Data Provided by the Centers for Disease Control and Prevention’s National Program of Cancer Registries and the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program, 2013-2017 [Varying]) * Chart Type: Comparative Data Table * Contextual Summary: This table presents age-adjusted incidence rates and percentage of cases for malignant brain and other central nervous system tumors in adults aged ≥20 years, stratified by sex and race/ethnicity, using data from 2013-2017. 2. Chart Structure and Elements * Axes/Headers: * Row Headers: Specific tumor types categorized under "Both sexes combined" and "Males". * Column Headers: * "ALL RACES" (subdivided into RATE and CASES, %) * "NON-HISPANIC WHITE" (subdivided into RATE and CASES, %) * "NON-HISPANIC BLACK" (subdivided into RATE and CASES, %) * "HISPANIC" (subdivided into RATE and CASES, %) * "ASIAN/PACIFIC ISLANDER" (subdivided into RATE and CASES, %) * "AMERICAN INDIAN/ALASKA NATIVE" (subdivided into RATE and CASES, %) * Legend/Groups: * The data is grouped by "Both sexes combined" and "Males". * Race/Ethnicity categories include "All Races", "Non-Hispanic White", "Non-Hispanic Black", "Hispanic", "Asian/Pacific Islander", and "American Indian/Alaska Native". * Tumor types include "All brain and CNS combined", "Tumors of neuroepithelial tissue" (with sub-categories like "Unique astrocytoma

Review source

Convert population evidence into a funnel: total affected → diagnosed → clinically eligible → treated → realistically accessible. Incidence, point prevalence and lifetime prevalence are not interchangeable. Do not pool incompatible age bands, case definitions or health systems.

For Klatskin Tumor, quantify diagnostic yield, severity distribution, center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges with a source and access date for every parameter. Market models should show which assumptions drive recruitment and adoption.

A small, well-defined population concentrated in expert centers may be more actionable than a larger population with poor diagnosis. Epidemiology therefore must connect to real patient identification, clinical eligibility and access.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: progression, incomplete control, toxicity, weak durability, burdensome delivery, diagnostic delay or absent options for a subgroup. Disease severity alone does not demonstrate that a program can deliver measurable benefit.

A strong Klatskin Tumor thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit is measurable within a feasible period and whether natural-history variability can be controlled.

Proceed through gates: confirm phenotype and natural history, demonstrate engagement, observe pharmacodynamic response, show interpretable clinical signal and only then scale. Pre-agreed stop criteria protect capital and make negative studies informative.

Target mechanism anchor: COL1A1

Type I collagen is a member of group I collagen (fibrillar forming collagen).

The mechanism anchor is COL1A1, a testable pathway hypothesis rather than a claim that every patient is target-dependent. Establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and therapeutic window.

Use orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit safety testing. Human evidence should carry more weight than model-only observations. Related failures should be analyzed for exposure, population and endpoint lessons.

A go decision requires a complete chain from relevant biology to achievable modulation, measurable pharmacodynamics and a plausible bridge to clinical benefit. Missing links require targeted experiments, not stronger narrative.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Clinical development and competition

The focused search returned 228 registered studies.

• NCT07745296 — Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer (SAFIR-IMPACT); Not yet recruiting; Phase 3; sponsor UNICANCER; enrollment 990.
• ChiCTR2600129357 — A Single-Center Retrospective Study of Clamp Test-Guided Biliary Management in Patients with Cholangiocarcinoma After Percutaneous Transhepatic Biliary Drainage Combined with Hepatic Arterial Infusion Chemotherapy (CCA-CLAMP2606); Not yet recruiting; Not Applicable; sponsor Beijing Tumor Hospital, Beijing Institute for Cancer Research; enrollment 50.
• NCT07621536 — Diagnostic Accuracy of Eus Fnb in Difficult to Reach Lesions; Completed; Not Applicable; sponsor not stated; enrollment 131.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies for one asset can inflate activity. Normalize records by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact subtype.

Compare against the likely future standard at launch. Whitespace may come from earlier treatment, genotype selection, durability, lower monitoring, safer chronic use or simpler delivery. Differentiation should be visible in protocol design and prospective analyses.

Recruitment risk requires site-density, testing, travel, competing-protocol and screen-failure assumptions. Natural-history evidence can reduce uncertainty but cannot substitute for controlled efficacy evidence when outcomes are variable.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering or broader asset-level indexing; add target and asset searches before valuation.

Separate upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope. A defensible comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires disease segmentation, target-validation chain, competition map, clinical plan, intellectual property, manufacturability evidence and a transparent risk-adjusted model. Outreach is strongest around a catalyst that retires material risk.

Low direct deal activity may represent whitespace, but can also signal difficult science or economics. Use broader therapeutic-area transactions only when relevance is explicit; rare-disease deals are not automatically interchangeable.

Market attractiveness and access

Attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, setting, payer controls, alternatives, monitoring and reimbursement. Patient count is only one driver. Reliable identification and meaningful benefit can support a small population; fragmented diagnosis can undermine a larger one.

Build scenarios for diagnosed prevalence, eligible share, timing, competition, net price, persistence and penetration. Keep assumptions traceable and refresh them when new epidemiology, trial or transaction evidence appears.

Begin payer research before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Quality of life, caregiver burden, hospital use and diagnostic costs may be essential to the value case.

Risks, decision gates and recommendation

• Confirm a consistently diagnosed and recruitable population.
• Demonstrate COL1A1 relevance in the selected phenotype.
• Connect engagement to a biomarker and meaningful endpoint.
• Refresh competition before every investment gate.
• Validate sites, testing, access, pricing and adoption.
• Treat zero-result searches as prompts for broader queries, not proof of absence.

Klatskin Tumor merits continued milestone-based evaluation if a coherent subgroup can be identified, target modulation can be measured and benefit remains differentiated against future care. The current evidence supports targeted diligence rather than unconditional investment.

The business-development objective is a partner-ready thesis covering patient segment, mechanism, whitespace, development path and value-inflection milestones. Evidence gaps should remain visible rather than hidden in a composite score.

Methodology and source note

This report was assembled on August 26, 2026 using Patsnap MCP tools: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and can change as databases update.

Weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease profile, epidemiology coverage, registered trials, development-drug counts and direct transactions. Rerun with synonyms, roll-ups, targets and assets before commitment.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Conclusion

The central question for Klatskin Tumor is whether a biologically grounded therapy can deliver material benefit in an identifiable population and remain differentiated through launch. This evidence provides a starting map; the explicit gaps define the next diligence plan.